FDA compliant tissue microarray 

AMSBIO reports that its extensive range of FDA tissue microarrays reliably enhances tissue cross-reactivity (TCR) and other target validation studies.

These high-quality tissue microarrays (TMAs) enable high-throughput analysis of a panel of tissue types recognized by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Each TMA features multiple normal tissue types from 3 different donor samples on a single slide to enable simultaneous analysis and facilitate the identification of potential cross-reactive and off-target epitopes that have not been previously observed. Gaining this insight early in the discovery process can help prevent costly mistakes that lead to inaccurate diagnostic test results or unwanted side effects from a therapeutic agent.

Based upon tissue cores verified and quality controlled by a board-licensed pathologist, these TMAs come pre-mounted and ready-to-use, minimizing consumable use via high-throughput, low-cost analysis with guaranteed quality assurance for clinical relevance. AMSBIO’s complete range of FDA TMAs are available in both frozen and FFPE tissue panels from human, rat, and mouse.

Dr Phillip Pridham-Field, AMSBIO’s Business Unit Manager for Biorepository commented “Our FDA compliant tissue microarrays offer a rapid and cost-effective direct method for the validation of biological targets in multiple tissue samples.”. He added “Parallel analysis of multiple specimens not only reduces operating times and conserves reagents, but also enables high-throughput molecular analysis of tissues.”

As well as FDA controls, AMSBIO offers over two thousand tissue microarrays for advanced biomarker and drug target validation research. All TMA are manufactured with samples from AMSBIO’s vast repository of normal human and animal tissue types, plus multiple tumor-type tissue arrays.

To learn more about FDA compliant TMA for comprehensive histological analysis, enabling study of protein, RNA, or DNA molecules across diverse samples please visit https://www.amsbio.com/biorepository/tissues/fda-tissue-arrays/ or contact AMSBIO on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products, and services for R&D in the medical, nutrition, cosmetics, and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion, and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins, and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognized as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cells and cell therapy applications. This includes GMP cryopreservation technology, and high-quality solutions for viral delivery.


Worldwide HQ

AMS Biotechnology (AMSBIO)
184 Milton Park
Oxon OX14 4SE

Tel: +44-1235-828200
Fax: +44-1235-820482
Web www.amsbio.com
North American HQ
1035 Cambridge Street
MA 02141

Tel:      +1.617.945.5033
Tel:      +1.800.987.0985 (toll free)
Web www.amsbio.com
Media Contact
Dr Bill Bradbury         info@primetek-solutions.com